BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Ron Renaud as a member of the company’s Board of Directors..

马萨诸塞州伯灵顿市。-（商业新闻短讯）--Cardurion Pharmaceuticals，Inc.（“Cardurion”或“该公司”）是一家临床阶段的生物技术公司，开发用于治疗心血管疾病的下一代疗法，今天宣布任命Ron Renaud为该公司董事会成员。。

Mr. Renaud brings more than 25 years of experience in evaluating, building, and leading biotechnology companies, with deep expertise in executive leadership, finance, and operations. His career underscores his commitment to advancing drug innovation in challenging disease areas, cultivating strong company organizations and cultures, and building significant value in leading-edge biopharma businesses, including as Chief Executive Officer of Cerevel Therapeutics, Translate Bio, and Idenix Pharmaceuticals..

雷诺先生在评估、建设和领导生物技术公司方面拥有超过25年的经验，在执行领导、财务和运营方面拥有深厚的专业知识。他的职业生涯突显了他致力于在具有挑战性的疾病领域推进药物创新，培养强大的公司组织和文化，并在领先的生物制药业务中创造重要价值，包括担任Cerevel Therapeutics，Translate Bio和Idenix Pharmaceuticals的首席执行官。。

“We are excited to welcome Ron to our Board of Directors. His outstanding track record building successful biotech companies and his business leadership experience and board expertise are ideally suited to Cardurion’s next stage of growth. We look forward to Ron’s contributions as we work to achieve major milestones with our ongoing phase two trials in heart failure and a rare arrhythmic disease, CPVT, as well as in the growth of our pipeline,” said Peter Lawrence, Chief Executive Officer of Cardurion..

Cardurion首席执行官彼得·劳伦斯（PeterLawrence）表示：“我们很高兴欢迎罗恩（Ron）加入我们的董事会。他在建立成功的生物技术公司方面的出色业绩记录，以及他的商业领导经验和董事会专业知识，非常适合Cardurion的下一个发展阶段。我们期待着罗恩（Ron）的贡献，因为我们正在进行心力衰竭和罕见心律失常性疾病CPVT的第二阶段试验，以及我们管道的发展。”。。

'I am delighted to join Cardurion’s board and to work with the company's board and management team that has made such impressive progress advancing drug candidates offering novel mechanisms to treat cardiovascular diseases,' said Mr. Renaud. “I look forward to offering my expertise to help drive Cardurion’s mission to bring new therapies to patients with CV diseases.”.

。“我期待着提供我的专业知识，帮助推动Cardurion为心血管疾病患者带来新疗法的使命。”。

Ron Renaud has served as Board member and Chairperson of numerous public and private biotechnology companies. He is currently a Senior Advisor to Bain Capital Life Sciences and serves as Chairperson at Upstream Bio. Ron was Cerevel Therapeutics’ President, Chief Executive Officer, and Board member, leading the company through a prolific period of raising capital, data readouts for neuroscience drug candidates and completion of the company’s acquisition by AbbVie for $8.7 billion in August 2024.

罗恩·雷诺（RonRenaud）曾担任众多公共和私人生物技术公司的董事会成员和主席。他目前是贝恩资本生命科学的高级顾问，并担任Upstream Bio的主席。罗恩是Cerevel Therapeutics的总裁、首席执行官和董事会成员，领导公司度过了一段多产的融资期，为神经科学候选药物读取数据，并于2024年8月完成了AbbVie以87亿美元收购该公司。

Prior to Cerevel, Mr. Renaud served as a partner at Bain Capital Life Sciences from September 2022 to June 2023. Previously, he led Translate Bio as Chairman and Chief Executive Officer beginning in 2014, transforming the company from a start-up platform into a leading mRNA company, culminating in an acquisition by Sanofi in September 2021 for $3.2 billion.

在加入Cerevel之前，雷诺先生于2022年9月至2023年6月担任贝恩资本生命科学公司的合伙人。此前，他从2014年开始领导Translate Bio担任董事长兼首席执行官，将公司从初创平台转变为领先的mRNA公司，最终于2021年9月被赛诺菲以32亿美元收购。

From 2007 through 2014, Mr. Renaud served in leadership roles at Idenix Pharmaceuticals as Chief Financial Officer, Chief Business Officer and finally, President and Chief Executive Officer, ultimately leading the company to an acquisition by Merck at a value of $3.85 billion..

从2007年到2014年，雷诺先生在Idenix Pharmaceuticals担任首席财务官、首席商务官，最后担任总裁兼首席执行官，担任领导职务，最终带领公司以38.5亿美元的价格被默克收购。。

Earlier in Mr. Renaud‘s career, he was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns. Mr. Renaud also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Mr. Renaud earned his bachelor’s degree from St.

在雷诺职业生涯的早期，他曾是摩根大通、施瓦布Soundview和贝尔斯登的生物技术股票研究分析师。。雷诺先生在圣路易斯大学获得学士学位。

Anselm College and an MBA from the Marshall School of Business at the University of Southern California..

安瑟姆学院（Anselm College）和南加州大学马歇尔商学院（Marshall School of Business）MBA。。

About Cardurion Pharmaceuticals

关于Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Cardurion was founded by physician-scientists with world-class expertise in cardiovascular signaling pathways, and a shared passion to find and develop a pipeline of novel treatment options to improve the lives of patients.

Cardurion Pharmaceuticals是一家临床阶段的生物技术公司，专注于发现和开发用于治疗心血管疾病的新型下一代疗法。Cardurion是由在心血管信号传导途径方面具有世界一流专业知识的医生科学家创立的，他们共同致力于寻找和开发一系列新的治疗方案，以改善患者的生活。

Cardurion has two groundbreaking clinical programs in development, a first-in-class phosphodiesterase-9 (PDE9) inhibitor for both types of chronic heart failure and the first-ever clinical-stage Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor for rare and common cardiovascular diseases..

Cardurion正在开发两个开创性的临床项目，一个是用于两种慢性心力衰竭的一流磷酸二酯酶-9（PDE9）抑制剂，另一个是用于罕见和常见心血管疾病的首次临床阶段钙/钙调蛋白依赖性蛋白激酶II（CaMKII）抑制剂。。

Cardurion Pharmaceuticals is headquartered in Burlington, Massachusetts, with discovery sciences and research facilities in Shonan, Japan. For more information, please visit the company’s website at https://cardurion.com.

Cardurion Pharmaceuticals总部位于马萨诸塞州伯灵顿，在日本Shonan拥有发现科学和研究设施。欲了解更多信息，请访问公司网站https://cardurion.com.